Search

Search Results

Found 8 items.

How do new therapeutic strategies for PCOS management influence the health of the affected individuals? The narrative review

Aleksandra Wójcik, Jan Wojtas, Mikołaj Margas, Konrad Warchoł, Karol Stępniak

294-300

2022-10-31
Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity.

Kamil Pondel, Kinga Kawałko, Krzysztof Bielewicz, Anna Chmura, Anna Karaś

55-60

2022-08-30
Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity

Magdalena Mazurek, Edyta Białowąs, Ewelina Dybała, Iwona Cuber, Artur Aghadi

196-205

2023-02-23
Current innovative treatments of obesity

Damian Wach, Aneta Głaz, Jolanta Wiśniewska, Zuzanna Radziejowska

227-241

2023-10-03
GLP-1 analogs in the treatment of obesity

Aleksandra Metelska, Jakub Metelski, Dominika Sereda, Hubert Nieścior

334-342

2022-08-06
Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Magdalena Mazurek, Edyta Białowąs, Ewelina Dybała, Iwona Cuber, Artur Aghadi

123-131

2023-02-20
Current and upcoming methods of pharmacotherapy of obesity

Jan Bieniasz, Konrad Dendys, Marcel Kazzi, Michał Puła, Marta Wychota

241-248

2023-02-26
Liraglutide as an innovative and multifunctional drug for patients with obesity – the current state of knowledge and future prospects

Maria Grodkiewicz, Paweł Kozieł, Klaudia Artykiewicz, Kamila Gorczyca, Marcin Czarkowski, Aleksandra Słupczyńska, Weronika Urbaś, Klaudia Podgórska, Aleksandra Puła, Urszula Krzysiek

153-160

2022-11-30

1 - 8 of 8 items